cGxP.wire https://validator.w3.org/feed/docs/rss2.html CellsBin Wins NCI Award to Advance Myeloma Blood Test Nyra Medical Expands Leadership as CARLEN Trial Advances AcuraStem Secures $1M Award to Advance AS-241 for ALS Tangram Therapeutics Doses First Participant in Phase 1 TGM-148 Clinical Trial OneOncology Reports Outpatient Tarlatamab Safety Findings Immunocore to Present Brenetafusp Phase 1 Data at SITC 2026 Amgen to Present New Autoimmune Disease Data at ACR 2026 OSE Immunotherapeutics Reports Positive Tedopi Phase 2 Results Lynk Reports Sustained Phase III Results for Zemprocitinib Assembly Bio Doses First Participants in Phase 2 ABI-6250 Study SEKISUI Launches FDA-Cleared COVID-19 and Flu Combo Test Guardant Health Welcomes Pennsylvania Shield Screening Law aTyr Pharma Publishes Phase 3 Efzofitimod Results in Lancet Artiva Ends AlloNK Development After Safety Review Philips Launches UniGuide 3D Live Guidance for Azurion AbbVie Seeks FDA Approval for Etentamig in Myeloma Treatment Helsinn Wins UK MHRA Approval for AKYNZEO Oral Suspension Astellas and Audax Sign $1.34B DAX-044 Cancer Drug Deal Element Biosciences Launches CE-Marked AVITI Dx in Europe Kelun Advances Sac-TMT for PD-L1-Negative Lung Cancer Novastra to Present OAP-101 Melanoma Data at SITC 2026 Vanda Reports Positive Phase 3 Results for NEREUS Iovance Reports 24.6% ORR for Lifileucel in Lung Cancer CervoMed Publishes New Neflamapimod Research in DLB Ono Pharmaceutical Reports ONO-1110 Phase 2 Results Exogenus Therapeutics Leads €13M EU Osteoarthritis Project Vivex Biologics Reports Positive ASCEND Trial Results for VIA Disc NP CREATE Medicines and WestGene Expand In Vivo CAR Pipeline Lamassu Biotech Reports Early Safety Data for SA53 Novellia Study Reveals Gaps in Ehlers-Danlos Patient Records Genmab Reports Positive Phase 3 Petosemtamab Combination Results in Head and Neck Cancer HUTCHMED Receives FDA Orphan Drug Designation for Sovleplenib in Immune Thrombocytopenia Idorsia and Nxera Pharma Expand Partnership as Phase 3 Lucerastat Study Begins Monte Rosa Therapeutics Earns $37.5M Milestone as Novartis Starts Second Phase 2 Trial of MRT-6160 Roche Launches VENTANA BAP1 Test to Improve Differential Diagnosis of Mesothelioma Nxera Pharma Secures Exclusive Asia Pacific Rights to Fabry Disease Candidate Lucerastat Mineralys Therapeutics Publishes Phase 2 Explore-CKD Results Supporting Lorundrostat’s Potential in Kidney Disease Adagene and Incyte Initiate Combination Trial of Muzastotug for Colorectal Cancer Madrigal Pharmaceuticals to Present Extensive Rezdiffra Evidence at AASLD The Liver Meeting 2026 Calidi Biotherapeutics Presents Promising CLD-401 and In Situ T-Cell Engager Data at ESMO 2026 CAMP4 Therapeutics Receives EU Approval to Advance CMP-002 Phase 1/2 Trial for SYNGAP1-Related Disorder Natera Highlights Signatera’s Potential in Bladder Cancer at ESMO 2026 Nautilus Biotechnology Joins ARPA-H-Funded Consortium to Study Alzheimer’s Disease and Cancer LUNGevity Launches Multi-Year Small Cell Lung Cancer Program Henlius Reports Positive U.S. Trial Results for Serplulimab Carnyx Therapeutics Advances Oral Sleep Drug CNYX-005 Atrium Therapeutics Starts First PRKAG2 Syndrome Trial Aclaris Therapeutics Reports Positive ATI-052 Phase 1b Results in Atopic Dermatitis and Asthma Cullinan Therapeutics Advances Velinotamig for Autoimmune Cytopenias RiboScience Reports Survival Data for Cancer Drug RBS2418